The association between longitudinal trends in receipt of buprenorphine for opioid use disorder and buprenorphine‐waivered providers in the United States

Abstract

AbstractAims, Design and SettingWe sought to describe longitudinal trends in buprenorphine receipt and buprenorphine‐waivered providers in the United States from 2003 to 2021 and measure whether the relationship between the two differed after capacity‐building strategies were enacted nationally in 2017. This was a retrospective study of two separate cohorts covering the years 2003–21, testing whether the association between two trends in these cohorts changed comparing 2003 to 2016 and from 2017 to 2021, among buprenorphine providers in the United States, regardless of treatment setting. Patients receiving dispensed buprenorphine at retail pharmacies.ParticipantsAll providers who have obtained a waiver to prescribe buprenorphine in the United States, and an estimate of the annual number of patients who had buprenorphine for opioid use disorder (OUD) dispensed to them at a retail pharmacy.MeasurementsWe synthesized and summarized data from multiple sources to assess the cumulative number of buprenorphine‐waivered providers over time. We used national‐level prescription data from IQVIA to estimate annual buprenorphine receipt for OUD.FindingsFrom 2003 to 2021, the number of buprenorphine‐waivered providers in the United States increased from fewer than 5000 in the first 2 years of Food and Drug Administration (FDA) approval to more than 114 000 in 2021, while patients receiving buprenorphine products for OUD increased from approximately 19 000 to more than 1.4 million. The strength of association between waivered providers and patients is significantly different before and after 2017 (P < 0.001). From 2003 to 2016, for each additional provider, there was an average increase of 32.1 [95% confidence interval (CI) = 28.7–35.6] patients, but an increase of only 4.6 (95% CI= 3.5–5.7) patients for each additional provider, beginning in 2017.ConclusionsIn the United States, the relationship between the rates of growth in buprenorphine providers and patients became weaker after 2017. While efforts to increase buprenorphine‐waivered providers were successful, there was less success in translating that into significant increases in buprenorphine receipt.